Literature DB >> 1689432

Comparative analysis of the action of class I antiarrhythmic drugs (lidocaine, quinidine, and prajmaline) in rabbit atrial and ventricular myocardium.

H Langenfeld1, J Weirich, C Köhler, K Kochsiek.   

Abstract

Effects of three class I antiarrhythmic drugs (quinidine, lidocaine, and prajmaline) on transmembrane resting (RMP) and action potentials (AP) of isolated rabbit atrial and ventricular myocardium were studied at different stimulation rates. The frequency-dependent depression of the maximal upstroke velocity (Vmax) of the AP (sodium channel block) was analyzed according to the "guarded receptor" hypothesis. The resting block (Vmax depression after a resting period) induced by prajmaline (10(-6) M), quinidine (2.2 x 10(-5) M), and lidocaine (4.3 x 10(-5) M) was more expressed in the atrium (44, 28, and 19%, respectively) than in the ventricle (32, 9, and 0%, respectively). There were also significant (p less than 0.05) atrioventricular differences in the frequency-dependent extra block (Vmax reduction on stimulation at 3.3 Hz) for quinidine (39 vs. 26%) and lidocaine (4 vs. 25%). From the analysis, according to the guarded receptor hypothesis, it follows that the three compounds bind preferentially to inactivated sodium channels with about the same affinity to the atrium and ventricle, except for quinidine which shows a significantly smaller dissociation constant in the atrium (5 x 10(-6) M vs. 2.7 x 10(-5) M; p less than 0.001). We conclude that the atrioventricular differences in the resting block are mainly due to atrioventricular differences in the RMP, whereas the differences in the frequency-dependent extra block are based on the shorter atrial AP duration (lidocaine) or are due to higher affinity to atrial sodium channels (quinidine).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689432     DOI: 10.1097/00005344-199002000-00023

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation.

Authors:  Charles Antzelevitch; Alexander Burashnikov
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 2.  Atrial-selective sodium channel blockers: do they exist?

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  J Cardiovasc Pharmacol       Date:  2008-08       Impact factor: 3.105

Review 3.  New pharmacological strategies for the treatment of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-07       Impact factor: 1.468

4.  Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.

Authors:  Alexander Burashnikov; José M Di Diego; Andrew C Zygmunt; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circulation       Date:  2007-09-04       Impact factor: 29.690

5.  Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation.

Authors:  Alexander Burashnikov; José M Di Diego; Andrew C Zygmunt; Luiz Belardinelli; Charles Antzelevitch
Journal:  Ann N Y Acad Sci       Date:  2008-03       Impact factor: 5.691

Review 6.  Atrial-selective sodium channel block for the treatment of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Expert Opin Emerg Drugs       Date:  2009-06       Impact factor: 4.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.